Hello, Welcome to Shine Consultant !
Summit & Event Shine Speaker Bureau Shine Advisor Shine Event Service
  • Summit & Event :
    With field research of markets and industries which is analyzed from a global strategic perspective by our professional teams, as well as hot topics which interest leadership and management, Shine Consultant provides you with one-stop platform of dialogue, practice -sharing and social network!
  • Shine Speaker Bureau:
    Committed to provide keynote speakers, executive learning masterclasses and boardroom advisory for global enterprises and institutions, each service provides a deeper and more interactive experience, especially for small, selected audiences and key individuals. We have the resources of the most influential business leaders and experts, who are the most outstanding representatives in their fields. Our team consists of experienced speech and event managers, and we focus on building long-term and in-depth partnerships.
  • Shine Advisor:
    As world-class insight network, we connects clients-decision makers with vetted subject matter experts-advisors. Our clients leverage the insights and perspectives shared by our advisors to stay informed and make better business decisions.We have over 600,000 Shine Advisors in 20 industries, which continues to grow every day.
  • Shine Event Service:
    Committed to be the world's most professional provider of industrial Summit & Event. We provide one-stop professional services, including investigating and planning, on-demand inviting, marketing and promoting, operating, project management, live& digital conference, each service is performed by an experienced professional team matched with long-term industrial resources. We focus on establishing long-term and in-depth partnerships.
Guest Information
Zhenping ZHU
Zhenping ZHU

President and CSO


Sunshine Guojian Pharmaceutical (Shanghai) Co.,Ltd.

朱祯平,现任三生国健药业总裁兼首席科学官,抗体药物国家工程研究中心主任,上海抗体工程技术研究中心主任。曾任三生制药集团研发总裁兼首席科学官,美国 Kadmon药业执行副总裁,瑞士Novartis生物制药副总裁,美国 ImClone Systems公司研发副总裁;参与及领导研发出多种美国FDA,欧洲EMA和中国NMPA批准上市的治疗性抗肿瘤抗体;他是ramucirumab (CyramzaR,雷莫芦) 和necitumumab (PortrazzaR,耐昔妥珠)的专利发明人,cetuximab (ErbituxR, 爱必妥)的主要贡献者。 朱博士曾就读于江西医学院(临床医学学士),中国医学科学院/北京协和医学院(药理学硕士),加拿大Dalhousie大学(免疫学和病理学博士),和美国Genentech公司(蛋白质和抗体工程博士后);1996年通过美国医生执业资格考试(USMLE)并获外国医学院毕业生在美国行医资格(ECFMG)证书;朱博士有超过35年在治疗性抗体领域研发的经历,包括28年在美国,欧洲和中国跨国药企研发和管理的经验。至今在国际刊物发表学术论文200余篇,包括第一或通讯作者100余篇。已申请或获得中国,美国和其它国际专利数超过100项。现任多个国际和国内生物制药公司董事会成员,包括三生国健,宜明昂科,Numab Therapeutics(瑞士),Refuge Biotechnologies(美国), 和 Verseau Therapeutics(美国).